Isoform-specific vs. pan-histone deacetylase inhibition as approaches for countering glioblastoma: an in vitro study

IntroductionGlioblastoma (GBM) is a grade 4 brain tumor that originates in astrocytes. GBM has a high death rate and a very low median patient survival rate of 14–16 months, even with well-established treatment regimens. The majority of preclinical models assess the effectiveness of molecular leads...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ameya Joshi, Natasha Ratnapradipa, Jayce Hughes, Erik Moore, Andrew Ekpenyong, Surabhi Shukla
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-11-01
Edice:	Frontiers in Oncology
Témata:	glioblastoma HDAC inhibitors Vorinostat Trichostatin-A Tubacin temozolomide
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1695552/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!